Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

AChR autoantibody subtype testing may improve accuracy of myasthenia gravis evaluations

Key clinical point: When testing for acetylcholine receptor (AChR) autoantibodies in patients with suspected myasthenia gravis, testing for binding antibodies and for modulating antibodies is more accurate than testing for either subtype alone.

Major finding: The sensitivity of testing for AChR binding autoantibodies was 92%, and the sensitivity of testing for modulating autoantibodies was 90%. In comparison, the sensitivity of testing for either antibody subtype or both was 94%.

Study details: A review of clinical and electrophysiologic testing data from 360 patients with suspected myasthenia gravis who underwent serologic autoantibody testing between 2012 and 2015.

Disclosures: The researchers had no relevant disclosures.

Citation:

Paul P et al. AANEM 2019, Abstract 236.